Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744621 | 0.80 | DHFR (0.56) | DHFR | |
| SCHEMBL6827626 | 0.78 | TDP1 (0.56) | DHFRMAPTRAB9AL3MBTL1 | |
| SCHEMBL6747595 | 0.78 | DHFR (0.52) | DHFR | |
| SCHEMBL6747511 | 0.78 | DHFR (0.64) | DHFRNPC1RAB9A | |
| SCHEMBL6745922 | 0.78 | DHFR (0.52) | DHFRTSHR | |
| SCHEMBL6747477 | 0.77 | DHFR (0.51) | DHFR | |
| SCHEMBL6748545 | 0.77 | DHFR (0.58) | DHFRMAPTMAPK1 | |
| SCHEMBL6751096 | 0.77 | DHFR (0.57) | DHFR | |
| SCHEMBL6744375 | 0.76 | DHFR (0.55) | DHFR | |
| SCHEMBL6748619 | 0.76 | DHFR (0.52) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092515-A1 | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | MELACURE THERAPEUTICS AB (SE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092515-A1 | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | DHFR, DPYD, DHODH | DHFR 1/4885SMN1; SMN2 2807/4885NPC1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.